XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Share-Based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
The components of the Company’s share-based compensation expense were as follows:
Three Months Ended March 31,
(in thousands)20242023
Stock options$1,346 $1,388 
Restricted stock3,477 3,699 
Performance vested restricted stock units4,271 4,684 
Total share-based compensation expense$9,094 $9,771 
A summary of the share-based award activity during the three months ended March 31, 2024 is presented below:
 Stock OptionsRestricted StockPerformance Vested
Restricted Stock Units
 OptionsWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life		SharesWeighted
Average
Grant Date
Fair Value		SharesWeighted
Average
Grant Date
Fair Value
Outstanding as of January 1, 2024943,641 $102.90 361,668 $136.05 458,495 $136.14 
Granted78,988 111.94 49,333 111.94 143,312 111.94 
Performance-based leveraging (1)
— — — — — — 
Exercised/vested(87,240)71.74 (37,307)105.52 (146,675)107.54 
Expired— — — — — — 
Forfeited(440)123.71 (2,433)119.50 (10,940)115.62 
Outstanding as of March 31, 2024934,949 $106.56 6.2 years371,261 $135.99 444,192 $138.29 
Options exercisable as of March 31, 2024639,175 $99.47 5.2 years
(1) During the three months ended March 31, 2024, there were no revisions to the outstanding PVRSUs as a result of a change in the Company's targeted performance conditions.
The fair value of the restricted stock and the PVRSUs with performance conditions that were granted during the three months ended March 31, 2024 was equal to the market price of the Company’s common stock on the date of the grant. The fair value of the PVRSUs with market conditions that are based on the Company’s total shareholder return relative to a predetermined peer group was estimated using a Monte Carlo simulation method as of the date of the grant. The requisite service periods for the restricted stock and the PVRSUs was between 9 months and 48 months. The PVRSUs have vesting ranges generally between 0% and 230% of the initial units granted.

The stock options granted by the Company had an exercise price that is equal to the market price of the Company's common stock on the date of grant. The fair value of the stock options granted during the three months ended March 31, 2024 was estimated on the grant date using the Black-Scholes option-pricing model with the following weighted average assumptions:
Risk-free interest rate4.27 %
Expected volatility31.34 %
Expected life of the stock option6 years
Dividend yield1.03 %
Requisite service period4 years
Contractual life10 years
Weighted average fair value of the stock options granted (per stock option)$38.85